Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Managing Your Care: Treatment and Lifestyle

At a Glance

ADPKD management focuses on slowing kidney cyst growth through rigorous blood pressure control (often targeting under 110/75 mmHg), reducing sodium intake, and staying hydrated. For patients at high risk of rapid disease progression, the medication tolvaptan can help slow cyst growth.

While there is currently no cure for ADPKD, the standard of care has advanced significantly. Treatment today focuses on two main goals: managing the factors that speed up the disease and using targeted medications to slow the growth of kidney cysts [1][2].

Blood Pressure: The “HALT-PKD” Strategy

Controlling blood pressure is the single most important thing you can do to protect your kidneys. The landmark HALT-PKD trial showed that for many patients with “preserved kidney function” (meaning early in the disease when your eGFR is still relatively normal), a “rigorous” blood pressure target is better than a “standard” one [3][4].

  • Standard Target: 120/70 to 130/80 mmHg [3].
  • Rigorous Target: 95/60 to 110/75 mmHg [3].

The study found that patients who maintained the more rigorous target had a 14.2% slower growth rate of their total kidney volume [3]. Most patients achieve these targets using ACE inhibitors or ARBs, which are medications that specifically protect the kidney’s filtering units [3].

Lifestyle Interventions

Your daily habits play a direct role in how hard your kidneys have to work.

  • Sodium Restriction: High salt intake forces the kidneys to work harder and can increase cyst fluid secretion. Reducing sodium is a cornerstone of ADPKD management [2].
  • Dietary Adjustments: Beyond salt, emerging research suggests that specific dietary modifications—such as plant-focused diets, managing oxalate intake, or even inducing ketosis—may help alter the cellular energy pathways that feed cysts. Always discuss major dietary changes with your doctor or a renal dietitian [2][5].
  • Hydration: Drinking enough water to suppress a hormone called vasopressin (which drives cyst growth) is often recommended, though you should discuss the exact amount with your doctor based on your kidney function [2].
  • Weight Management: Being overweight or having a high BMI is linked to faster progression to kidney failure in ADPKD [6].

Targeted Treatment: Tolvaptan (Jynarque)

Tolvaptan is the first FDA-approved medication specifically for ADPKD [7]. It works as a V2 receptor antagonist, meaning it blocks the hormone vasopressin from “turning on” the growth of cysts [8][9].

Who is it for?

Tolvaptan is reserved for patients at high risk for “rapid progression,” typically those in Mayo Imaging Classes 1C, 1D, or 1E [10][11].

What are the risks and side effects?

  • Aquaretic Effects: Because the drug blocks the body’s ability to concentrate urine, it causes polyuria (frequent urination), polydipsia (extreme thirst), and the need to wake up multiple times at night to urinate [7][12].
  • Dehydration Risk Warning: Because the drug forces massive amounts of water out of your body, you must pause the medication and contact your doctor immediately if you become ill (e.g., vomiting, gastroenteritis) or undergo a surgery that prevents you from drinking water. Continuing tolvaptan without continuous access to water can lead to rapid, life-threatening dehydration and dangerous blood sodium levels (hypernatremia) [12].
  • Hepatotoxicity (Liver Risk): In rare cases, tolvaptan can cause serious liver injury [13][14]. Because of this, it is only available through a safety program (REMS) that requires monthly blood tests to monitor liver function for the first 18 months, and then every three months thereafter [13][15].

What happens if I stop?

Deciding to stop tolvaptan is a significant choice. Research suggests that once the medication is discontinued, the rate of kidney growth and function decline can accelerate back to your original baseline rate [16][17]. While the benefits you gained while on the drug (like the delay in reaching kidney failure) may persist for a while, the protective “slowing” effect ends when the medication stops [18][19].

Common questions in this guide

What is the ideal blood pressure target for ADPKD?
For many patients early in the disease, a rigorous blood pressure target between 95/60 and 110/75 mmHg may help slow kidney cyst growth. This is typically managed using ACE inhibitors or ARBs, which protect the kidney's filtering units.
How does tolvaptan (Jynarque) help treat ADPKD?
Tolvaptan blocks a hormone called vasopressin, which is responsible for stimulating the growth of kidney cysts. It is typically prescribed for patients who have specific imaging results indicating a high risk for rapid disease progression.
What are the side effects of taking tolvaptan?
The most common side effects are extreme thirst and frequent urination, including the need to wake up at night to urinate. Because it forces water out of the body, there is a risk of severe dehydration if you become ill or cannot drink enough fluids.
Why is a low-sodium diet important for ADPKD?
High salt intake forces your kidneys to work harder and can actually increase the secretion of fluid into kidney cysts. Reducing your daily sodium is a cornerstone of managing ADPKD and protecting your kidney function.
What happens if I stop taking my tolvaptan medication?
If you discontinue the medication, the protective slowing effect on your kidneys ends. Research shows that the rate of kidney growth and functional decline can accelerate back to your original baseline rate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the HALT-PKD study, is a 'rigorous' blood pressure target (below 110/75) appropriate for me at my current stage?
  2. 2.What is my daily sodium limit, and how much water should I be drinking to help suppress vasopressin?
  3. 3.Do I meet the 'rapid progressor' criteria (Mayo Class 1C-1E) that would make me eligible for tolvaptan?
  4. 4.Can you explain the liver monitoring schedule required for tolvaptan and what happens if my enzymes become elevated?
  5. 5.How will we manage the increased urination (polyuria) if I start taking tolvaptan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.

    Riyahi S, Dev H, Blumenfeld JD, et al.

    Journal of magnetic resonance imaging : JMRI 2021; (53(2)):564-576 doi:10.1002/jmri.27360.

    PMID: 32969110
  2. 2

    Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

    Steele CN, Nowak KL

    Advances in kidney disease and health 2023; (30(3)):220-227 doi:10.1053/j.akdh.2022.12.008.

    PMID: 37088524
  3. 3

    Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

    Brosnahan GM, Abebe KZ, Moore CG, et al.

    Current hypertension reviews 2018; (14(1)):39-47 doi:10.2174/1573402114666180322110209.

    PMID: 29564978
  4. 4

    Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

    Brosnahan GM, Abebe KZ, Moore CG, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (71(5)):666-676 doi:10.1053/j.ajkd.2017.10.023.

    PMID: 29306517
  5. 5

    A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.

    Mader G, Mladsi D, Sanon M, et al.

    BMC nephrology 2022; (23(1)):334 doi:10.1186/s12882-022-02956-8.

    PMID: 36258169
  6. 6

    Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.

    Nowak KL, Copeland TP, Ku E, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2025; (20(4)):520-528 doi:10.2215/CJN.0000000640.

    PMID: 39970002
  7. 7

    Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.

    Sans-Atxer L, Joly D

    International journal of nephrology and renovascular disease 2018; (11()):41-51 doi:10.2147/IJNRD.S125942.

    PMID: 29430193
  8. 8

    The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.

    Patergnani S, Giattino A, Bianchi N, et al.

    Biology of the cell 2023; (115(1)):e2200037 doi:10.1111/boc.202200037.

    PMID: 36165233
  9. 9

    Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome.

    Roca Oporto FJ, Rocha JL

    Clinical kidney journal 2022; (15(4)):827-828 doi:10.1093/ckj/sfab260.

    PMID: 35371438
  10. 10

    Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.

    Shoaf SE, Bricmont P, Repella Gordon J

    Clinical and translational science 2021; (14(4)):1535-1542 doi:10.1111/cts.13017.

    PMID: 33742787
  11. 11

    Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort.

    Calvaruso L, Yau K, Akbari P, et al.

    Scientific reports 2023; (13(1)):22257 doi:10.1038/s41598-023-48638-9.

    PMID: 38097698
  12. 12

    Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

    Raina R, Houry A, Rath P, et al.

    Drug, healthcare and patient safety 2022; (14()):147-159 doi:10.2147/DHPS.S338050.

    PMID: 36105663
  13. 13

    Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease.

    Bellos I

    Therapeutics and clinical risk management 2021; (17()):649-656 doi:10.2147/TCRM.S286952.

    PMID: 34234441
  14. 14

    Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.

    Watkins PB, Lewis JH, Kaplowitz N, et al.

    Drug safety 2015; (38(11)):1103-13 doi:10.1007/s40264-015-0327-3.

    PMID: 26188764
  15. 15

    A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

    Chebib FT, Perrone RD, Chapman AB, et al.

    Journal of the American Society of Nephrology : JASN 2018; (29(10)):2458-2470 doi:10.1681/ASN.2018060590.

    PMID: 30228150
  16. 16

    Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.

    Lioudis M, Zhou X, Davenport E, et al.

    BMC nephrology 2023; (24(1)):182 doi:10.1186/s12882-023-03247-6.

    PMID: 37349694
  17. 17

    Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

    Torres VE, Chapman AB, Devuyst O, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(3)):477-489 doi:10.1093/ndt/gfx043.

    PMID: 28379536
  18. 18

    Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

    Edwards ME, Chebib FT, Irazabal MV, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2018; (13(8)):1153-1161 doi:10.2215/CJN.01520218.

    PMID: 30026287
  19. 19

    Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.

    Muto S, Okada T, Shibasaki Y, et al.

    Clinical and experimental nephrology 2021; (25(9)):1003-1010 doi:10.1007/s10157-021-02083-y.

    PMID: 34089122

This page provides educational information about ADPKD treatment and lifestyle management. Always consult your nephrologist or renal dietitian before changing your blood pressure targets, diet, or medications.

Get notified when new evidence is published on Autosomal dominant polycystic kidney disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.